Cell line · CVCL_Y003
Papers70
1 to 20 of 70
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Low-Density Lipoprotein Receptor-Targeted Biomimetic Nanoplatform Suppresses Glioblastoma Stemness and Remodels Antitumor Immunity via Dual Metabolic Disruption. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SQOR regulates H2S detoxification and lipid metabolism to maintain glioblastoma metabolic fitness. | Res Sq | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting LDHA Palmitoylation Sensitizes GBM to Chemoradiotherapy via Suppressing Palmitic Acid Induced Glycolytic Reprogramming. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LRIG2 suppresses NK cell-induced GSDME-mediated pyroptosis via the LAMP1-STAT3 pathway in glioma. | J Immunother Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Surface-engineered milk-derived extracellular vesicles enable oral miRNA therapy against immunosuppressive pancreatic cancer. | Mater Today Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sonoselective Transfection of Glioma Endothelium. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A novel oncolytic herpes simplex virus type 2 induces polarization of tumor-associated macrophages and remodels the immune microenvironment in glioblastoma. | Cancer Immunol Immunother | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| H2S induces apoptosis of tumors with high IDO1 expression via NR4A1-BCL-2 and SOCS3 pathways. | Cell Mol Biol Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IL6 Supports Development of an Immunosuppressive Microenvironment and Resistance to Therapy in Glioblastoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-associated macrophages promote ferroptosis resistance in glioblastoma by stimulating iron-loaded extracellular vesicle release. | J Neurooncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the tumor microenvironment: reprogramming macrophages as a novel therapeutic strategy in FUOM-deficient glioblastoma. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Glioma-induced DNMT3A reduction in microglia promotes an anti-tumoral phenotype. | Cell Death Differ | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Neuron-glioma synaptic transmission amplified by free 19S proteasome-mediated AMPAR deubiquitination promotes tumor progression. | Neurotherapeutics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Engineered Small Extracellular Vesicles Targeting Tumor-Associated Endothelial Cells to Effectively Remodel the Glioma Microenvironment. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Systemic cyst(e)inase administration induces ferroptosis and synergizes with temozolomide in glioblastoma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Astrocytic PCBP1 Suppresses Ferroptosis to Restore Glutamatergic Homeostasis and Mitigate Stress-Induced Depression in Male Mice. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ZBTB7B inhibits glioma tumorigenicity by upregulating GPR17 and CXCL10. | J Mol Cell Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| C5aR1 Inhibition Alleviates Cranial Radiation-Induced Cognitive Decline. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Ultra-Sensitive Wireless Capacitive Nanocomposite-Based Pressure Sensors for Health Monitoring. | Adv Mater Technol | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_Y003/papers